Skip to main content
BC Innovations
Feature Story

Cardio reboot

Why Philip Sager thinks better preclinical tools can spur drug development

By Steve Edelson, Executive Editor of New Media

A two-year-old FDA initiative is progressing toward its goal of replacing clinical QT studies with preclinical assays that do a better job at predicting proarrhythmia side effects. The question is what impact replacing QT will have on early drug development.

To discuss the issue, BioCentury sat down with Philip Sager, a cardiologist and consulting professor of medicine at Stanford University School of Medicine. He also sits on FDA's Cardiovascular and Renal Drugs Advisory Committee and is a consultant for Sager Consulting Experts Inc.

Read Article

Today's Biotech & Pharma News

  • COVER STORY

    Tools & Techniques: Nixing antibody aggregation

    Newco Solvanix's technology can reduce the aggregation of mAbs by introducing as few as two mutations, without affecting binding or immunogenicity.

  • STRATEGY

    Cardio reboot

    Cardiologist Philip Sager says the current thinking on preclinical cardiovascular safety involves new ways of looking at ion conductance to replace QT, and might enable or rescue many compounds.

  • Adding Up for AD

    NIH's meeting with G7 health leaders coincided with three announcements about AD funding, and stakeholders are optimistic the field is starting to get some much-needed attention.

  • TOOLS

    T as in transplants

    A T cell-based fingerprint in the plasma of kidney transplant recipients could identify patients who will develop tolerance and not need immunosuppressive therapy.

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial